CQ29. Is Chemotherapy Effective for Advanced or Relapsed Medullary Carcinoma?



We studied the literature for the effectiveness of chemotherapy on advanced or relapsed medullary thyroid carcinoma with no indications for surgery, where tangible tumors were detectable on palpation or imaging studies. Serum cacitonin level and CEA level are sensitive tumor markers of medullary carcinoma and these elevations are often initial signs of recurrence before findings on imaging studies, but no reports are available for chemotherapy for cases without relapsed tumors for which sizes can be measured.


Liver Metastasis Tumor Shrinkage Initial Sign Medullary Carcinoma Relapse Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Petursson SR (1988) Metastatic medullary thyroid carcinoma: complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 62:1899–1903 (CR)PubMedCrossRefGoogle Scholar
  2. 2.
    Gottlieb JA, Hill CS Jr (1974) Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 290:193–197 (RS)PubMedCrossRefGoogle Scholar
  3. 3.
    Shimaoka K, Schoenfeld DA, DeWys WD et al (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160 (RCT)PubMedCrossRefGoogle Scholar
  4. 4.
    Scherübl H, Raue F, Ziegler R (1990) Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116:21–23 (PS)PubMedCrossRefGoogle Scholar
  5. 5.
    Orlandi F, Caraci P, Berruti B et al (1994) Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5:763–765 (RS)PubMedGoogle Scholar
  6. 6.
    Wu LT, Averbuch SD, Ball DW et al (1994) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73:432–436 (RS)PubMedCrossRefGoogle Scholar
  7. 7.
    Schlumberger M, Abdelmoumene N, Delisle MJ et al (1995) Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. Br J Cancer 71:363–365 (unknown study design)PubMedCrossRefGoogle Scholar
  8. 8.
    Nocera M, Baudin E, Pellegriti G et al (2000) Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Br J Cancer 83:715–718 (RS)PubMedCrossRefGoogle Scholar
  9. 9.
    Matuszczyk A, Petersenn S, Bockisch A et al (2008) Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 40:210–213 (RS)PubMedCrossRefGoogle Scholar
  10. 10.
    Lorenz K, Brauckhoff M, Behrmann C et al (2005) Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 138:986–993 (PS)PubMedCrossRefGoogle Scholar
  11. 11.
    Fromigué J, De Baere T, Baudin E et al (2006) Chemoembolization for liver metastases from medullary thryoid carcinoma. J Clin Endocrinol Metab 91:2496–2499 (PS)PubMedCrossRefGoogle Scholar
  12. 12.
    Lupoli G, Cascone E, Arlotta F et al (1996) Treatment of advanced medullary thyroid carcinoma with a combination of recombiant interferon alpha-2b and octreotide. Cancer 78:1114–1118 (RS)PubMedCrossRefGoogle Scholar
  13. 13.
    Mahler C, Verhelst J, De Longueville M et al (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 33:261–269 (RS)CrossRefGoogle Scholar
  14. 14.
    Modigliani E, Cohen R, Joannidis S et al (1992) Results of long-term continuous subcutaneous ocreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol 36:183–186 (RS)CrossRefGoogle Scholar
  15. 15.
    Diez JJ, Iglesias P (2002) Somatostatin analogs in the treatment of medullary thyroid carcinoma. J Endocrinol Invest 25:773–778 (RS)PubMedGoogle Scholar
  16. 16.
    Vitale G, Tagliaferri P, Caraglia M et al (2000) Slow release lanreotide in combination with interferon-alpha 2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 85:983–988 (unknown study design)PubMedCrossRefGoogle Scholar
  17. 17.
    British Thyroid Associations & Royal College of Physicians (2007) Guidelines for the management of thyroid cancer in adults, 2nd edn. www.british-thyroid-association.org
  18. 18.
    Cooper DS, Doherty GM, Haugen BR et al (2006) American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109–142, http://www.thyroid.org/professionals/publications/documents/Guidelinesthy2006.pdf PubMedCrossRefGoogle Scholar
  19. 19.
    NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma (2009) v1. http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf
  20. 20.
    Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612, http://www.thyroid.org/professionals/publications/documents/MTC_Guidelines.pdf PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  1. 1.Department of SurgeryNoguchi Thyroid Clinic and Hospital FoundationBeppuJapan
  2. 2.Department of Breast and Endocrine SurgeryToranomon HospitalTokyoJapan
  3. 3.Department of Endocrine Surgery and Hygiene & Public Health IITokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations